Recursion Pharmaceuticals (NASDAQ: RXRX), a small-cap biotech company, has one claim to fame: It currently owns the largest ...

Author Shawn Peters blends clarity and rigor to make data structures and algorithms accessible to all learners. COLORADO, CO, UNITED STATES, January 2, 2026 /EINPresswire.com/ — Vibrant Publishers ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

新年伊始，MIT CSAIL 的一纸论文在学术圈引发了不小的讨论。Alex L． Zhang 、 Tim Kraska 与 Omar Khattab 三位研究者在 arXiv 上发布了一篇题为《Recursive Language ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

2026年的AI范式或许已悄然发生了剧变。在过去的一年里，人工智能领域的长文本处理能力经历了前所未有的飞速发展。从128k到1M再到10M的上下文窗口（Context Window）内卷化过程，表面上看似技术的进步，但实际上却隐藏着深层次的问题。基于Transformer注意力机制的线性扩张，正面临着物理与效果的双重边际递减，这让我们不得不重新思考AI的未来。